Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Immuron Limited ( (AU:IMC) ) just unveiled an update.
Immuron Limited has announced the quotation of 2,579,760 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date of January 8, 2025. This move is part of transactions previously announced and potentially strengthens Immuron’s position in the biotechnology market by increasing its financial resources and market visibility.
More about Immuron Limited
Immuron Limited operates in the biotechnology industry, specializing in the development and commercialization of oral immunotherapy products for the treatment of various diseases. The company’s primary market focus includes innovative treatments for gut health and immune-related conditions.
YTD Price Performance: -2.50%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €10.88M
For a thorough assessment of IMC stock, go to TipRanks’ Stock Analysis page.
